BMS-986278 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
85Idiopathic interstitial pneumonia4

85. Idiopathic interstitial pneumonia


Clinical trials : 627 Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003992-21-IT
(EUCTR)
15/12/202030/08/2021A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants with Lung FibrosisA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis Pulmonary Fibrosis
MedDRA version: 21.0;Level: PT;Classification code 10037383;Term: Pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 21.1;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BMS-986278
Product Code: [BMS-986278]
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
Product Name: BMS-986278
Product Code: [BMS-986278]
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIONNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
360Phase 2United States;Taiwan;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Belgium;Australia;Germany;Japan;Korea, Republic of
2EUCTR2019-003992-21-DE
(EUCTR)
06/08/202027/05/2020A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants with Lung FibrosisA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis Pulmonary Fibrosis
MedDRA version: 21.0;Level: PT;Classification code 10037383;Term: Pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 21.1;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BMS-986278
Product Code: BMS-986278
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
Product Name: BMS-986278
Product Code: BMS-986278
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
Bristol-Myers Squibb International CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
360Phase 2United States;Taiwan;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Canada;Argentina;Brazil;Belgium;Australia;Germany;Japan;Korea, Republic of
3EUCTR2019-003992-21-BE
(EUCTR)
03/07/202004/05/2020A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary FibrosisA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis Pulmonary Fibrosis
MedDRA version: 21.0;Level: PT;Classification code 10037383;Term: Pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
MedDRA version: 21.1;Classification code 10021240;Term: Idiopathic pulmonary fibrosis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BMS-986278
Product Code: BMS-986278
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
Product Name: BMS-986278
Product Code: BMS-986278
INN or Proposed INN: LPA1
Other descriptive name: BMS-986278
Bristol-Myers Squibb International CorporationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
360Phase 2United States;Spain;Chile;Israel;United Kingdom;Italy;France;Mexico;Canada;Argentina;Belgium;Brazil;Australia;Germany;Japan;Korea, Republic of
4NCT03981094
(ClinicalTrials.gov)
May 10, 201921/5/2019A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsAn Open Label Study to Assess the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 Following a Single Oral Dose Administration in Healthy ParticipantsIdiopathic Pulmonary Fibrosis (IPF)Drug: BMS-986278;Drug: PirfenidoneBristol-Myers SquibbNULLCompleted21 Years65 YearsAll22Phase 1United States